07:00 , Oct 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Mucopolysaccharidosis N-acetylglucosaminidase-a (NAGLU); insulin-like growth factor-2 (IGF-2); mannose-6-phosphate receptor (M6P receptor) Mouse studies suggest a NAGLU-IGF-2...
08:00 , Mar 5, 2001 |  BioCentury  |  Emerging Company Profile

Novazyme: Getting the translation right

The point of doing targeted therapy is that it generally requires a smaller amount of medication compared to systemic therapy, which relies on diffusion of drug to the site of action. Novazyme Inc. is trying...